KPTI

Karyopharm Therapeutics Inc. [KPTI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

KPTI Stock Summary

Top 10 Correlated Stocks

KPTI


In the News

09:41 29 Mar 2024 KPTI

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.43 per share a year ago.

01:37 29 Mar 2024 KPTI

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.

11:06 29 Mar 2024 KPTI

Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know

Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

02:25 29 Mar 2024 KPTI

Karyopharm Therapeutics Inc. (KPTI) Q3 2023 Earnings Conference Call Transcript

Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President and CEO Reshma Rangwala - Chief Medical Officer Sohanya Cheng - Chief Commercial Officer Michael Mason - CFO Conference Call Participants Maury Raycroft - Jefferies Colleen Kusy - Baird Operator Good morning. My name is Guru and I will be your conference operator today.

10:48 29 Mar 2024 KPTI

Penny Stocks To Buy Now? 3 With Ratings Up To 1,742%

In a stock market characterized by growing unpredictability, traders are leaning on every possible resource. One such indispensable tool, whether dealing with penny stocks or more expensive shares, is the insight provided by analysts.

10:28 29 Mar 2024 KPTI

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.62 per share a year ago.

08:09 29 Mar 2024 KPTI

Why Is Karyopharm Therapeutics (KPTI) Stock Up 21% Today?

Karyopharm Therapeutics (NASDAQ: KPTI ) stock is climbing higher on Tuesday after getting fast-track designation for its myelofibrosis treatment. The Food and Drug Administration (FDA) has granted fast-track designation to the development of selinexor.

01:02 29 Mar 2024 KPTI

All You Need to Know About Karyopharm Therapeutics (KPTI) Rating Upgrade to Buy

Karyopharm Therapeutics (KPTI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

04:05 29 Mar 2024 KPTI

Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings

NEWTON, Mass. , May 23, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2-6 in Chicago, Illinois and the 2023 European Hematology Association (EHA) Hybrid Congress, being held June 8-11 in Frankfurt, Germany.

07:46 29 Mar 2024 KPTI

Karyopharm Therapeutics, Inc. (KPTI) Q1 2023 Earnings Call Transcript

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Michael Mason - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Kevin Strang - Jefferies Colleen Kusy - Robert W. Baird Nicole Gabreski - Piper Sandler Eric Joseph - JPMorgan Operator Good morning.

KPTI Financial details

Company Rating
Neutral
Market Cap
159.94M
Income
-143.1M
Revenue
146.03M
Book val./share
-1.19
Cash/share
1.67
Dividend
-
Dividend %
-
Employees
325
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-0.7
Forward P/E
-1.45
PEG
0.18
P/S
0.67
P/B
-0.98
P/C
0.91
P/FCF
-1.4
Quick Ratio
3.97
Current Ratio
3.98
Debt / Equity
-1.28
LT Debt / Equity
-1.25
-
-
EPS (TTM)
-1.25
EPS next Y
-1.05
EPS next Q
-0.33
EPS this Y
-38.12%
EPS next Y
-16%
EPS next 5Y
-94%
EPS last 5Y
-17.24%
Revenue last 5Y
28.99%
Revenue Q/Q
-6.28%
EPS Q/Q
20%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
50.84%
Inst Trans
0.71%
ROA
-52%
ROE
239%
ROC
-0.6%
Gross Margin
96%
Oper. Margin
-86%
Profit Margin
-96%
Payout
-
Shs Outstand
115.07M
Shs Float
105.69M
-
-
-
-
Target Price
9
52W Range
0.617-4.87
52W High
-
52W Low
-
RSI
59
Rel Volume
0.5
Avg Volume
1.83M
Volume
921.9K
Perf Week
8.93%
Perf Month
17.31%
Perf Quarter
18.22%
Perf Half Y
27.08%
-
-
-
-
Beta
0.003
-
-
Volatility
0.05%, 0.12%
Prev Close
3.04%
Price
1.525
Change
8.16%

KPTI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.661.52.791.921.28
Net income per share
-3.22-2.72-1.65-2.02-1.25
Operating cash flow per share
-3.08-2.22-1.42-1.83-0.81
Free cash flow per share
-3.08-2.23-1.5-1.83-0.81
Cash per share
4.233.463.043.41.68
Book value per share
0.80.7-1.06-0.2-1.19
Tangible book value per share
0.80.7-1.06-0.2-1.19
Share holders equity per share
0.80.7-1.06-0.2-1.19
Interest debt per share
2.052.042.632.421.73
Market cap
1.19B1.12B483.65M278.36M98.8M
Enterprise value
1.17B1.15B462.49M316.15M222.93M
P/E ratio
-5.95-5.68-3.9-1.68-0.69
Price to sales ratio
29.0410.322.311.770.68
POCF ratio
-6.22-6.96-4.52-1.86-1.07
PFCF ratio
-6.22-6.95-4.29-1.86-1.07
P/B Ratio
23.8622.06-6.07-16.71-0.73
PTB ratio
23.8622.06-6.07-16.71-0.73
EV to sales
28.5810.612.22.011.53
Enterprise value over EBITDA
-6.35-6.8-4.73-2.26-1.73
EV to operating cash flow
-6.12-7.16-4.32-2.11-2.4
EV to free cash flow
-6.12-7.15-4.1-2.11-2.4
Earnings yield
-0.17-0.18-0.26-0.59-1.45
Free cash flow yield
-0.16-0.14-0.23-0.54-0.94
Debt to equity
2.242.37-2.15-10.39-1.28
Debt to assets
0.380.380.560.480.72
Net debt to EBITDA
0.1-0.190.22-0.27-0.96
Current ratio
5.9974.883.54.963.37
Interest coverage
-12.1-6.33-3.77-5.69-5.44
Income quality
0.960.820.860.90.65
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
01.170.690.930.9
Research and developement to revenue
2.991.40.770.950.95
Intangibles to total assets
00000
Capex to operating cash flow
000.0500
Capex to revenue
-0.010-0.0300
Capex to depreciation
-0.21-0.15-7.24-0.190
Stock based compensation to revenue
0.370.230.140.230.15
Graham number
7.636.566.273.045.8
ROIC
-1.07-0.94-0.95-0.86-3.18
Return on tangible assets
-0.68-0.63-0.41-0.46-0.6
Graham Net
0.37-0.03-1.83-0.73-1.43
Working capital
227.32M289.24M184.38M260.84M164.44M
Tangible asset value
49.77M50.55M-79.67M-16.66M-136.21M
Net current asset value
28.48M27.04M-126.88M-48.08M-142.72M
Invested capital
2.242.37-2.15-10.39-1.28
Average receivables
3.93M10.37M17.69M34.79M37.02M
Average payables
2.66M2.72M3.03M2.19M2.95M
Average inventory
173K1.5M3.38M4.17M3.63M
Days sales outstanding
70.1743.539.14109.4267.39
Days payables outstanding
149.37600.46171.99194.16208.31
Days of inventory on hand
52.47356.77440.53295.75202.98
Receivables turnover
5.28.399.333.345.42
Payables turnover
2.440.612.121.881.75
Inventory turnover
6.961.020.831.231.8
ROE
-4.01-3.881.569.921.05
Capex per share
00-0.0800

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.370.340.330.310.29
Net income per share
-0.43-0.3-0.29-0.3-0.36
Operating cash flow per share
-0.3-0.17-0.23-0.26-0.16
Free cash flow per share
-0.3-0.17-0.23-0.26-0.16
Cash per share
3.092.292.11.821.67
Book value per share
-0.19-0.4-0.63-0.88-1.19
Tangible book value per share
-0.19-0.4-0.63-0.88-1.19
Share holders equity per share
-0.19-0.4-0.63-0.88-1.19
Interest debt per share
1.991.581.631.571.57
Market cap
305.78M441.44M201.41M153.3M99.28M
Enterprise value
343.56M527.69M298.59M280.34M223.41M
P/E ratio
-1.99-3.23-1.54-1.11-0.59
Price to sales ratio
9.1111.415.364.262.94
POCF ratio
-11.39-23.34-7.84-5.19-5.34
PFCF ratio
-11.42-23.34-7.84-5.19-5.34
P/B Ratio
-18.36-9.77-2.83-1.53-0.73
PTB ratio
-18.36-9.77-2.83-1.53-0.73
EV to sales
10.2313.647.957.796.62
Enterprise value over EBITDA
-10.56-18.64-11.21-9.86-5.92
EV to operating cash flow
-12.8-27.91-11.62-9.49-12.02
EV to free cash flow
-12.84-27.91-11.62-9.49-12.02
Earnings yield
-0.13-0.08-0.16-0.23-0.42
Free cash flow yield
-0.09-0.04-0.13-0.19-0.19
Debt to equity
-10.39-3.84-2.5-1.73-1.28
Debt to assets
0.480.530.60.640.72
Net debt to EBITDA
-1.16-3.05-3.65-4.47-3.29
Current ratio
4.964.834.943.983.37
Interest coverage
-5.76-5.37-5.11-5.15-6.09
Income quality
0.70.550.790.860.44
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.030.930.920.860.91
Research and developement to revenue
0.920.840.840.991.16
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
0.70000
Stock based compensation to revenue
0.180.140.160.140.15
Graham number
1.341.642.032.443.12
ROIC
-0.21-0.23-0.26-0.39-0.93
Return on tangible assets
-0.11-0.1-0.11-0.13-0.17
Graham Net
-0.66-0.73-0.94-1.15-1.42
Working capital
260.84M235.51M232.45M185.09M164.44M
Tangible asset value
-16.66M-45.17M-71.25M-100.4M-136.21M
Net current asset value
-48.08M-73.91M-77.7M-123.19M-142.72M
Invested capital
-10.39-3.84-2.5-1.73-1.28
Average receivables
37.27M41.14M33.74M35.1M32.44M
Average payables
1.79M5.91M5.67M1.62M2.03M
Average inventory
4.24M4.03M3.75M3.39M3.07M
Days sales outstanding
126.281.8677.3194.7871.91
Days payables outstanding
133.6602.55172.3993.16179.83
Days of inventory on hand
203.51254.94276.78306.75175.22
Receivables turnover
0.711.11.160.951.25
Payables turnover
0.670.150.520.970.5
Inventory turnover
0.440.350.330.290.51
ROE
2.310.760.460.340.31
Capex per share
00000

KPTI Frequently Asked Questions

What is Karyopharm Therapeutics Inc. stock symbol ?

Karyopharm Therapeutics Inc. is a US stock , located in Newton of Ma and trading under the symbol KPTI

Is Karyopharm Therapeutics Inc. buy or a sell ?

3 stock analysts have 3 predictions with a medium analyst target price of $9. The lowest prediction is $5 and the highest is $14

What is KPTI stock prediction ?

What is Karyopharm Therapeutics Inc. stock quote today ?

Karyopharm Therapeutics Inc. stock price is $1.525 today.

Is Karyopharm Therapeutics Inc. stock public?

Yes, Karyopharm Therapeutics Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap